Effect of taVNS on Heart Rate in Persistent Atrial Fibrillation

Launched by BURRELL COLLEGE OF OSTEOPATHIC MEDICINE · Jul 6, 2023

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment called transcutaneous auricular vagus nerve stimulation (taVNS) for people with persistent atrial fibrillation, a condition where the heart beats irregularly and can be fast or slow. The treatment involves applying a small electrical current to a specific spot on the left ear. Researchers want to find out if this method can help lower the heart rate in patients with this condition. Participants in the study will use a small device to administer the treatment themselves for 30 minutes every day over two weeks. During this time, their heart activity will be monitored using a small patch on their chest to see if there are any changes in heart rate.

To be eligible for this trial, participants must be at least 18 years old and have persistent atrial fibrillation. They also need to be on blood-thinning medication throughout the study. However, individuals under 18, pregnant women, and those with certain medical conditions, like hearing issues or epilepsy, cannot participate. Throughout the study, participants will meet with the research team at the beginning, after one week, and at the end of the two weeks to discuss their experiences and results. This trial is not yet recruiting, but it aims to provide valuable insights into a potential new way to manage heart health in those with persistent atrial fibrillation.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • At least 18 years of age
• • Persistent atrial fibrillation
• • On anti-coagulation throughout the study
• Exclusion Criteria:
• • Below 18 years of age
• • Pregnancy
• • Signs or history of vestibulocochlear neuronitis or nerve damage (e.g., hearing loss or tinnitus)
• • Signs or history of epilepsy
• • Not on anti-coagulation